Prior Authorization Reform for Autoimmune and Blood Disorders Act
Key claim: HR9192 proposes to reform prior authorization requirements for autoimmune and blood disorders, referred to House committees on Energy and Commerce, Education and Workforce, and Ways and Means.
Abstract
(HR9192 · 119th Congress) Latest action (2026-06-08): Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Why this matters
Prior authorization is a primary friction point between MPN patients and access to prescribed therapies, particularly for costly or specialty drugs used in blood disorders. A bill explicitly targeting autoimmune and blood disorder prior authorization could, if enacted, directly change the administrative steps required before MPN treatments are approved by payers. At the introduced stage with referrals to three House committees, the proposal signals policy attention but has no immediate operational effect.